Additionally, recent findings from the updated TAILOR-X trial, which included patients with node-negative, ER+HER2- breast cancer, have shown that the risk of late recurrence after 5 years surpasses that of early recurrence within the first 5 years (8). Here, ESR1 is linked to breast carcinoma.